RQ Biotechnology Ltd. (RQ Bio) has announced that the first of its discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients, AZD-3152, has entered clinical trials.
Novelmed Therapeutics Inc. has reported topline results with its lead anti-properdin antibody NM-3086 in a rabbit model of paroxysmal nocturnal hemoglobinuria (PNH). NM-3086 is a potent, first-in-class, humanized monoclonal antibody that is highly selective for properdin of the alternative pathway (AP) without blocking the classical pathway (CP), which is critical for maintaining host defense against infections.
NK cell-based cancer immunotherapy has emerged as an anticancer treatment approach and is currently being tested in clinical trials. KIR2DL5, a member of the human killer cell immunoglobulin-like receptor (KIR) family, has recently been identified as a binding partner for poliovirus receptor (PVR). However, the biology and therapeutic potential of the KIR2DL5/PVR pathway remain widely unexplored.
Tonix Pharmaceuticals Holding Corp. has entered into a sponsored research agreement with Boston Children's Hospital to study TNX-1500, an Fc-modified anti-CD40L monoclonal antibody, for the prevention of graft-vs.-host disease (GVHD) after hematopoietic stem cell transplant (HSCT) in animals.
Mast cells (MCs) are tissue-resident immune cells and are responsible for allergic and inflammatory processes. One potential approach for targeting MCs is to engage inhibitory receptors that can silence MC activation, such as sialic acid-binding immunoglobulin-like lectins (siglecs). Siglec-6 is an inhibitory receptor expressed on human MCs and represents an attractive therapeutic target for this purpose. Siglec-6 engagement with a monoclonal antibody (MAb) was recently shown to inhibit MC activation in vitro.
Exelixis Inc. and Sairopa BV have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class monoclonal antibody that targets SIRPα.
China's National Medical Products Administration (NMPA) has cleared an IND application for a clinical trial of Shanghai Henlius Biotech Inc.'s HLX-60 for the treatment of solid tumors and lymphomas.
Endpoint Health Inc. has announced a new precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling.
RSS
